Clinical evidence and rationale of mesoglycan to treat chronic venous disease and hemorrhoidal disease: a narrative...

Area of Science:

• Vascular Medicine
• Pharmacology
• Biochemistry

Background:

• Chronic venous disease (CVD) and hemorrhoidal disease (HD) are prevalent vascular conditions impacting quality of life and incurring significant healthcare costs.
• Both CVD and HD share etiological factors and pathological changes in the extracellular matrix, affecting tissue structure and function.
• Current treatments range from lifestyle modifications and topical therapies to oral medications and surgery, depending on disease severity.

Purpose of the Study:

• To evaluate the efficacy of mesoglycan, a glycosaminoglycan preparation, in managing chronic venous disease (CVD) and hemorrhoidal disease (HD).
• To assess mesoglycan's impact on the underlying pathophysiology of CVD and HD, including endothelial function and extracellular matrix integrity.
• To analyze mesoglycan's effects on clinical outcomes such as symptom severity, quality of life, and healing rates.

Main Methods:

• Review of clinical trial data investigating the effects of oral mesoglycan in patients with CVD and HD.
• Analysis of mesoglycan's pharmacological actions, including its role in glycocalyx regeneration, endothelial function, and anti-inflammatory properties.
• Assessment of outcomes in patients with CVD (symptoms, quality of life, ulcer healing) and HD (symptoms, bleeding, postoperative recovery).

Main Results:

• Oral mesoglycan demonstrated significant reductions in CVD signs and symptoms, improved health-related quality of life (HRQoL), and accelerated ulcer healing.
• In HD patients, mesoglycan significantly decreased symptom severity and the incidence of rectal bleeding.
• Post-hemorrhoidectomy, mesoglycan as an adjunct to standard care reduced pain, improved HRQoL, lowered thrombosis risk, and expedited return to normal activities.

Conclusions:

• Mesoglycan's clinical benefits in CVD and HD are consistent with its demonstrated mechanisms of action, including glycocalyx regeneration and improved endothelial function.
• Mesoglycan offers a therapeutic option that addresses the underlying pathology of these common vascular diseases.
• The findings support the use of mesoglycan for improving patient outcomes and quality of life in both chronic venous and hemorrhoidal diseases.